| 31.67 -1.49 (-4.49%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.8 |
1-year : | 47.88 |
| Resists | First : | 34.93 |
Second : | 41 |
| Pivot price | 33.35  |
|||
| Supports | First : | 25.12 |
Second : | 20.9 |
| MAs | MA(5) : | 32.59 |
MA(20) : | 32.58 |
| MA(100) : | 27.04 |
MA(250) : | 156.3 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 43.1 |
D(3) : | 46.6 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 910 | Low : | 15.1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IRLA ] has closed above bottom band by 29.6%. Bollinger Bands are 9.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.16 - 34.39 | 34.39 - 34.58 |
| Low: | 30.8 - 31.01 | 31.01 - 31.18 |
| Close: | 31.36 - 31.7 | 31.7 - 31.99 |
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
Tue, 03 Nov 2026
Price to book forward of IRulya Therapeutics Inc. – NASDAQ:IRLA - TradingView
Fri, 30 Oct 2026
IRulya Therapeutics Inc. (IRLA) company profile and facts - Yahoo Finance UK
Fri, 30 Oct 2026
IRulya Therapeutics Inc. (IRLA) Seasonal returns chart - Yahoo Finance UK
Thu, 29 Oct 2026
IRulya Therapeutics Inc. (IRLA) insider ownership and holdings - Yahoo Finance UK
Thu, 29 Oct 2026
IRulya Therapeutics Inc. (IRLA) valuation measures and financial statistics - Yahoo Finance UK
Thu, 29 Oct 2026
IRulya Therapeutics Inc. (IRLA) interactive stock chart - Yahoo Finance UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 11.6 (%) |
| Shares Short | 60 (K) |
| Shares Short P.Month | 57 (K) |
| EPS | -214.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -34.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.6 % |
| Return on Equity (ttm) | -153.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -59.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.15 |
| PEG Ratio | 0 |
| Price to Book value | -0.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|